Effect of Levosimendan Compared to Conventional Inotropic Agents on Hemodynamics and Outcome in Patient with Poor LV Function Undergoing Cardiac Surgery

Mahmoud Khaled; Ahmad Naem Almogy; Mohamed Shehata; Fahim Ragab; Khaled Zeineldein

doi:10.3889/oamjms.2019.675

Authors

Mahmoud Khaled Department of Critical Care Medicine, Cairo University, Cairo, Egypt
Ahmad Naem Almogy Department of Critical Care Medicine, Cairo University, Cairo, Egypt
Mohamed Shehata Department of Critical Care Medicine, Cairo University, Cairo, Egypt
Fahim Ragab Department of Critical Care Medicine, Cairo University, Cairo, Egypt
Khaled Zeineldein Department of Critical Care Medicine, Cairo University, Cairo, Egypt

DOI:

https://doi.org/10.3889/oamjms.2019.675

Keywords:

levosimendan, cardiac surgery, conventional inotropes

Abstract

BACKGROUND: Patients undergoing heart surgery involving cardiopulmonary bypass (CPB) experience global myocardial ischemia with subsequent reperfusion which, despite cardioplegic protection, may result in different degrees of transient ventricular dysfunction. Levosimendan is a â€œcalcium sensitisersâ€, it improves myocardial contractility by sensitising troponin C to calcium without increasing myocardial oxygen consumption and without impairing relaxation and diastolic function.

AIM: To evaluate the adding effect of a calcium sensitiser (levosimendan) compared to the conventional inotropic and vasoactive agent used in the patient with poor left ventricular function undergoing cardiac surgery on different measured hemodynamic variables and the effect on the outcome.

METHODS: It is prospective observational studies were patients were divided into 2 groups of 30 patients each. The first Group received conventional inotropic and vasoactive treatment at different doses, while the other group received levosimendan additionally at a loading dose of 6-12mic/kg according to mean arterial pressure over 0.5 hr followed by 24 hrs infusion at 0.05 to 0.2 mic/kg/min. Hemodynamic data were collected at the end and 30 minutes after CPB, after that at 6, 12, 24, and 36 hours post CPB. Mean arterial pressure (MAP), central venous pressure (CVP), heart rate (HR), mixed venous saturation (Svo2), and base deficit (BD) were measured.

RESULTS: Levosimendan had significantly improved postoperative hemodynamic values as in the mixed venous pressure at different times postoperative (p < 0.05), also the base deficit at different times postoperative (p < 0.05), while there was a significant reduction in systemic vascular resistance as decreased mean arterial pressure in levosimendan group compared to conventional group at 6hrs postoperative mean 77.50 Â± 10.81 vs 83.73 Â± 10.81 with (p = 0.029), and at 12 hrs postoperative mean 77.37 Â± 10.10vs 84.23 Â± 13.81 with (p = 0.032), and there was no significant difference in heart rate at different times postoperative between both groups (p > 0.05), while there was no significant effect on mortality between both groups (p = 0.781).

CONCLUSION: Levosimendan had improved hemodynamic parameters significantly with no effect on mortality compared to conventional inotropic agents in a patient with poor left ventricular function undergoing cardiac surgery.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Breisblatt WM, Stein KL, Wolfe CJ, et al. Acute myocardial dysfunction and recovery: a common occurrence after coronary bypass surgery. JAmCollCardiol. 1990; 15:1261-1269. https://doi.org/10.1016/S0735-1097(10)80011-7

Doyle AR, Dhir AK, Moors AH, Latimer RD. Treatment of perioperative low cardiac output syndrome. The Annals of thoracic surgery. 1995; 59:S3-11. https://doi.org/10.1016/0003-4975(94)00916-U

Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. The Journal of thoracic and cardiovascular surgery. 1996; 112(1):38-51. https://doi.org/10.1016/S0022-5223(96)70176-9

Butterworth JF, Legault C, Royster RL, et al. Factors that predict the use of positive inotropic drug support after cardiac valve surgery. Anesth Analg. 1998; 86:461-467. https://doi.org/10.1213/00000539-199803000-00002 PMid:9495394

Romson JL, Leung JM, Bellows WH, et al. Effects of dobutamine on hemodynamics and left ventricular performance after cardiopulmonary bypass in cardiacsurgical patients. Anesthesiology. 1999; 91:1318-1328. https://doi.org/10.1097/00000542-199911000-00024 PMid:10551583

Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. The Annals of thoracic surgery. 2002; 73(1):325-30. https://doi.org/10.1016/S0003-4975(01)02719-9

Figgitt DP, Gillies PS, Goa KL. Levosimendan drugs. 2001; 61:613-627. https://doi.org/10.2165/00003495-200161050-00006 PMid:11368286

McBride BF, White CM. Levosimendan: implications for clinicians. The Journal of Clinical Pharmacology. 2003; 43(10):1071-81. https://doi.org/10.1177/0091270003257217 PMid:14517189

Frishman WH. Advances in positive inotropic therapy: levosimendan. Critical care medicine. 2003; 31(9):2408-9. https://doi.org/10.1097/01.CCM.0000084861.07091.F3 PMid:14501979

Lehtonen L. Levosimendan a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Investig Drugs. 2001; 10:955-970. https://doi.org/10.1517/13543784.10.5.955 PMid:11322869

Kersten JR, Montgomery MW, Pagel PS. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. AnesthAnalg. 2000; 90:5-11. https://doi.org/10.1097/00000539-200001000-00003 PMid:10624967

Janssen P M L, Datz N, Zeitz O, et al. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol. 2000; 404:191-199. https://doi.org/10.1016/S0014-2999(00)00609-9

De Luca L, Sardella G, Proietti P, Battagliese A, Benedetti G, Di Roma A, Fedele F. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. Journal of the American Society of Echocardiography. 2006; 19(2):172-7. https://doi.org/10.1016/j.echo.2005.08.016 PMid:16455421

Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, Venetsanou K, Lekakis J, Kremastinos DT. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. The American journal of cardiology. 2005; 96(3):423-6. https://doi.org/10.1016/j.amjcard.2005.03.092 PMid:16054474

Givertz MM, Andreou C, Conrad CH, et al. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: Alteration of force-frequency and relaxation-frequency relationships. Circulation. 2007; 115; 1218-1224. https://doi.org/10.1161/CIRCULATIONAHA.106.668640 PMid:17339544

Sonicki RM. Levosimendan as a new strategy during off-pump coronary artery bypass grafting: double-blind randomized placebo-controlled trial. Croat Med J. 2005; 46(6):950-6.

Barisin S, Husedzinovic I, Sonicki Z, et al. Levosimendan in off-pump coronary bypass: a four times masked controlled study. J Cardiovasc Pharmacol. 2004; 44:703-8. https://doi.org/10.1097/00005344-200412000-00013 PMid:15550791

De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesthesia & Analgesia. 2007; 104(4):766-73. https://doi.org/10.1213/01.ane.0000256863.92050.d3 PMid:17377079

Malliotakis PO, Xenikakis TH, Linardakis MA, Hassoulas JO. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series. Hellenic J Cardiol. 2007; 48(2):80-88.

Gandham R, Syamasundar A, Ravulapalli H, Karthekeyan RB, Vakamudi M, Kodalli R, Nandipati S. A comparison of hemodynamic effects of levosimendan and dobutamine in patients undergoing mitral valve repair/ replacement in sever mitral stenosis. Ann Card Anaesth. 2013; 16:11-5. https://doi.org/10.4103/0971-9784.105363 PMid:23287080

Alvarez J et al. evaluating the hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Rev EspCardiol. 2006; 59(4):338-45. https://doi.org/10.1016/S1885-5857(06)60770-6

Al-Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi R. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. Journal of cardiothoracic and vascular anesthesia. 2006; 20(3):353-7. https://doi.org/10.1053/j.jvca.2006.02.012 PMid:16750735

Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, Harrison RW, Hay D, Fremes S, Duncan A, Soltesz EG. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. New England Journal of Medicine. 2017; 376(21):2032-42. https://doi.org/10.1056/NEJMoa1616218 PMid:28316276